Unknown

Dataset Information

Epigenetic signatures in antidepressant treatment response: a methylome-wide association study in the EMC trial.


ABSTRACT: Although the currently available antidepressants are well established in the treatment of the major depressive disorder (MDD), there is strong variability in the response of individual patients. Reliable predictors to guide treatment decisions before or in an early stage of treatment are needed. DNA-methylation has been proven a useful biomarker in different clinical conditions, but its importance for mechanisms of antidepressant response has not yet been determined. 80 MDD patients were selected out of >500 participants from the Early Medication Change (EMC) cohort with available genetic material based on their antidepressant response after four weeks and stratified into clear responders and age- and sex-matched non-responders (N = 40, each). Early improvement after two weeks was analyzed

SUBMITTER: Engelmann J 

PROVIDER: S-EPMC9259740 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature